146 related articles for article (PubMed ID: 23295806)
1. Prognostic and predictive markers in metastatic renal cell carcinoma.
Khattak MA; Bakr F; Krzystanek M; Szallasi Z; Gerlinger M; Santos C; Swanton C; Pickering LM; Gore ME; Larkin JM
J Clin Oncol; 2013 Mar; 31(7):971-2. PubMed ID: 23295806
[No Abstract] [Full Text] [Related]
2. Reply to M A Khattak et al.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2013 Mar; 31(7):972-3. PubMed ID: 23565533
[No Abstract] [Full Text] [Related]
3. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
[TBL] [Abstract][Full Text] [Related]
4. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
Procopio G; Verzoni E; De Braud F
Eur Urol; 2012 Jul; 62(1):e5-6; author reply e7-8. PubMed ID: 22487015
[No Abstract] [Full Text] [Related]
5. [Role of mTOR inhibition in the treatment of metastatic renal cell carcinoma].
Mizuno R; Miyajima A; Oya M
Nihon Jinzo Gakkai Shi; 2012; 54(5):581-5. PubMed ID: 22991836
[No Abstract] [Full Text] [Related]
6. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors.
Roca S; Quivy A; Gross-Goupil M; Bernhard JC; De Clermont H; Ravaud A
Acta Oncol; 2011 Oct; 50(7):1135-6. PubMed ID: 21726178
[No Abstract] [Full Text] [Related]
7. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
[No Abstract] [Full Text] [Related]
8. Pneumocystis jirovecii pneumonia in everolimus-treated renal cell carcinoma.
Loron MC; Grange S; Guerrot D; Di Fiore F; Freguin C; Hanoy M; Le Roy F; Poussard G; Etienne I; Legallicier B; Pfister C; Godin M; Bertrand D
J Clin Oncol; 2015 Mar; 33(8):e45-7. PubMed ID: 24638002
[No Abstract] [Full Text] [Related]
9. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
Grgic T; Mis L; Hammond JM
Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
[TBL] [Abstract][Full Text] [Related]
10. Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.
Jebali M; Elaidi R; Brizard M; Fouque J; Takouchop C; Sabatier B; Oudard S; Medioni J
BMC Cancer; 2017 Jan; 17(1):27. PubMed ID: 28061764
[TBL] [Abstract][Full Text] [Related]
11. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
Bukowski RM
Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
[No Abstract] [Full Text] [Related]
12. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor.
Rothermundt C; Gillessen S
J Clin Oncol; 2013 Feb; 31(5):e57-8. PubMed ID: 23295800
[No Abstract] [Full Text] [Related]
13. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
Gerullis H; Ecke TH; Eimer C; Heuck CJ; Otto T
Minerva Urol Nefrol; 2010 Dec; 62(4):411-23. PubMed ID: 20944541
[TBL] [Abstract][Full Text] [Related]
14. Everolimus- and temsirolimus-associated enteritis: report of three cases.
Parithivel K; Ramaiya N; Jagannathan JP; O'Regan K; Krajewski K; Fisher D; Choueiri TK; Jacobsen E
J Clin Oncol; 2011 May; 29(14):e404-6. PubMed ID: 21357780
[No Abstract] [Full Text] [Related]
15. Prolonged efficacy of mTOR inhibitors in papillary renal cell carcinoma: progression-free survival lasting for over 3 years, a case report and review of the literature.
Daste A; Gross-Goupil M; Roca S; Bernhard JC; Ravaud A
Target Oncol; 2014 Mar; 9(1):81-4. PubMed ID: 23283668
[TBL] [Abstract][Full Text] [Related]
16. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
[No Abstract] [Full Text] [Related]
17. Everolimus.
Atkins MB; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2009 Jul; 8(7):535-6. PubMed ID: 19568281
[No Abstract] [Full Text] [Related]
18. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma.
Li S; Kong Y; Si L; Chi Z; Cui C; Sheng X; Guo J
BMC Cancer; 2014 May; 14():376. PubMed ID: 24886512
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors of response to treatment in patients with metastatic renal cell carcinoma: new evidence.
Tonini G; Fratto ME; Imperatori M; Pantano F; Vincenzi B; Santini D
Expert Rev Anticancer Ther; 2011 Jun; 11(6):921-30. PubMed ID: 21707289
[TBL] [Abstract][Full Text] [Related]
20. The clinical potential of temsirolimus in second or later lines of treatment for metastatic renal cell carcinoma.
Stenner-Liewen F; Grünwald V; Greil R; Porta C
Expert Rev Anticancer Ther; 2013 Sep; 13(9):1021-33. PubMed ID: 24024788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
